ADVERTISEMENT
ADVERTISEMENT
site_logo
  • Campus
  • Happening
  • Opinion
  • People
  • News
  • #BeInspired
  • Careers
  • 40 under 40
  • Exams
  • What The FAQ
  • Videos
    • Straight Up
    • Odisha Literary Festival 2020
    • Campus Convo
    • Careers After Corona
    • Express Expressions
    • Q&A With Prabhu Chawla
    • ThinkEdu Awards 2020
  • Web Stories
  • edex_worksEDEXWORKS
ADVERTISEMENT
COVID

Published: 12th October 2021     

Covaxin gets nod from India's Central Drug Authority to give to children aged 2 to 18 years. But it's not for everyone

When DGCI will grant final approval, Covaxin will be the second vaccine for the use of kids after Zydus Cadila's three-dose DNA jab is used for children above 12 years

Edex Live
Edex Live
f_icon t_icon i_icon l_icon koo_icon whatsapp_icon email_icon Google News

Share Via Email

Flu

Representational image (Picture: Express illustrations)

The Central Drug Authority of India has recommended granting emergency use authorisation to Bharat Biotech's Covaxin for children in the age group of 2 to 18 years on October 12. However, the authorities have put certain terms and conditions in place before granting the use of vaccine. 

Bharat Biotech which is based in Hyderabad completed the phase 2/3 trails of COVID vaccine Covaxin for use in children aged between 2 to 18 years. They submitted the data to the Central Drugs Standard Control Organisation for verification and approval for Emergency Use Authorisation in the beginning of October. As per their data, the tests were conducted on over 1,000 children across India. And it was noted that the vaccine trial showed similar impact as it shows on adults.  

The Subject Expert Committee (SEC) on COVID-19 examined the data and deliberated on the EUA application on Monday. After detailed deliberation, the committee recommended grant of market authorisation of the vaccine for the age group of 2 to 18 years for restricted use in emergency situations subject to certain conditions. The recommendations of the SEC have been sent to the Drugs Controller General of India (DCGI) for final approval.

When DGCI will grant final approval, Covaxin will be the second vaccine for the use of kids after Zydus Cadila's three-dose DNA jab is used for children above 12 years. The third vaccine for kids is Novavax by Serum Institute. For this, the DGCI has cleared trails for children aged between 7 and 11 years. Similarly, Corbevax by Biological E has been cleared to conduct trials on children aged above 5 

telegram
TAGS
COVID Vaccination Children Bharat Biotech

O
P
E
N

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
telegram
ADVERTISEMENT
Write to us!

If you have campus news, views, works of art, photos or just want to reach out to us, just drop us a line.

newsletter_icon
Mailbox
edexlive@gmail.com
fb_icon
Facebook
twitter_icon
Twitter
insta_icon
Instagram
ADVERTISEMENT
Facebook
ADVERTISEMENT
Tweets by Xpress_edex
ADVERTISEMENT
ADVERTISEMENT

FOLLOW US

The New Indian Express | The Morning Standard | Dinamani | Kannada Prabha | Samakalika Malayalam | Cinema Express | Indulgexpress | Events Xpress

Contact Us | About Us | Privacy Policy | Terms of Use

Home | Live Now | Live Story | Campus Trip | Coach Calling | Live Take

Copyright - edexlive.com 2023. All rights reserved. Website Designed, Developed & Maintained by Express Network Private Ltd.